Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to
bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain,
headaches, clay colored stools etc.
Hepatitis is caused by a variety of factors both microbial and non-microbial. However
hepatitis C is caused by hepatitis C virus and affects between 130–150 million people
globally every year of which approximately 700 000 people die from hepatitis C-related liver
diseases. What is of greater concern is the fact that 15 to 20% of chronically infected
patients develop liver cirrhosis or liver cancer.
The market for hepatitis C is driven by factors such as disease prevalence, rise in
government subsidy and reimbursement especially in U.S., greater screening especially in
developing nations, drug abuse and unsafe sex etc.
However the restraints are overwhelming such as self-imitating nature of the disease in a
sizable number of patients, challenge of herbal treatment offered at negligible prices
especially in developing regions, price war between companies such as between Gilead and
Merck, rising urbanization and better sanitation etc. Thus the market in developed regions
appears to reach a plateau as the number of people affected is not rising in developed
regions. The reevaluation of hepatitis C strategy by companies such as Boehringer
Ingelheim and its decision to refrain from moving forward in hepatitis C research also is an
indication of stagnancy in developed region markets.
Some of the key players in this market are: Gilead sciences Inc., Abbvie Inc, Johnson &
Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb,
Hoffmann-la Roche ltd. and others. Get Demo Copy at http://bit.ly/2unWEPF .
The market is also unitary with a few dominant players such as Gilead with a few brands
such as Sovaldi, Harvoni etc are leading the market. The development pipeline is however
strong in the vaccine segment and it is expected that a vaccine will make its foray in the
near future as happened with other forms of hepatitis.
Taking into consideration all factors the market for global hepatitis drugs was estimated to
rise from $18700 million to $22721.1 million by the end of forecasting period reflecting a
sluggish CAGR of 3.3%.
Segments: Global hepatitis c drugs market has been segmented on the basis of drug class
which comprises anti-viral, immuno-modulators and others. On the basis of medicine
system; market is segmented into allopathic, alternative and others. On the basis of route
of administration; market is segmented into oral, injectable and others. On the basis of end
user the market is segmented into hospitals and private.
Regional Analysis of Global Hepatitis C Drugs Market: Globally America is the largest market
for Hepatitis C drugs. Europe is the second-largest market for Hepatitis C drugs. The
developed regions market is expected to remain stagnant and even may show negative
CAGR due to falling patient’s number. Thus market of developing nations however will show
moderate growth and is expected to catch on the developed regions. The Asia pacific region